Welcome to our dedicated page for Silence Therapeutics Plc SEC filings (Ticker: SLN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Silence Therapeutics plc filings document a foreign biotechnology issuer whose American Depositary Shares trade on Nasdaq under SLN, with each ADS representing three ordinary shares. The record includes 8-K reports furnishing quarterly and annual financial results, business highlights, Regulation FD presentations and other events tied to siRNA pipeline development.
The company’s disclosures also cover proxy materials for shareholder voting and governance, board composition, executive departures and appointments, committee changes, and the relationship between listed ADSs and ordinary shares. Clinical and business exhibits describe programs from the mRNAi GOLD platform, including SANRECO updates for divesiran in polycythemia vera and collaboration-related disclosures involving AstraZeneca.
Silence Therapeutics plc (SLN) – Form 4 insider activity: Director and 10% owner Richard Ian Griffiths, through Cream Capital Ltd., reported two open-market purchases of American Depositary Shares (ADS).
- 31 Jul 2025: 14,342 ADS at $6.18
- 1 Aug 2025: 4,034 ADS at $6.14
The combined 18,376 ADS cost roughly $113 k and lifted his indirect holding to 11,825,861 ADS. Each ADS converts into three ordinary shares and has no expiration date. Griffiths disclaims beneficial ownership beyond his pecuniary interest.
The transactions modestly increase an already large position (<0.02 % incremental) and do not affect control status, but fresh insider buying can be viewed as a mild vote of confidence. No sales, options, or other derivative moves were disclosed.
Silence Therapeutics plc (SLN) – Form 4 insider buying
10% owner Richard Ian Griffiths, via Cream Capital Ltd., disclosed open-market purchases on 21-22 Jul 2025 of 25,345 American Depositary Shares (ADS) at $6.04 and $6.09. Each ADS converts into three ordinary shares, increasing his indirect holding by roughly 76,035 ordinary shares.
Post-trade, Griffiths’ beneficial position totals ≈11.78 million ADS-equivalent shares. No sales were reported. Continued accumulation by a 10% holder generally signals confidence in the company’s outlook and may support sentiment toward SLN shares.
Silence Therapeutics (NASDAQ:SLN) filed a routine Form 8-K disclosing voting results from its 26 June 2025 Annual General Meeting. Shareholders approved all 13 resolutions, including the re-appointment of directors David Lemus, Tim McInerney, Iain Ross and Craig Tooman; an annual non-binding say-on-pay vote; ratification of PricewaterhouseCoopers LLP as both U.S. and U.K. auditors; adoption of the 2024 U.K. statutory accounts; and replacement of the company’s articles of association. Support levels exceeded 90% for most items (e.g., Craig Tooman re-elected with 78.23 M votes for vs. 28.4 k against). The board will continue to seek shareholder input on executive compensation annually. No other material business, strategic changes or financial disclosures were announced.
Silence Therapeutics Plc (SLN) – Schedule 13D/A Amendment No. 9
The filing discloses the updated beneficial ownership of long-time shareholder Richard Ian Griffiths and several Jersey-based entities he controls. After recent open-market activity and an increase in the company’s share capital, Mr. Griffiths now reports 34,543,302 ordinary shares (held directly and through seven entities), representing 24.4 % of SLN’s 141,690,849 outstanding shares. Voting and dispositive power for all shares is held solely by Mr. Griffiths.
Recent transactions: Between 8 May 2025 and 24 Jun 2025, Mr. Griffiths purchased an additional 543,581 ADSs on the open market for a combined cash consideration of US $2.7 million; each ADS equals three ordinary shares. These purchases were funded with personal or affiliated-company cash.
Entity breakdown:
- Ora Capital Ltd – 19,221,525 ordinary shares (13.6 %)
- Sarossa Plc – 1,815,522 shares
- Cream Capital Ltd – 3,967,896 shares
- Blake Holdings Ltd – 300,000 shares
- Ora Ventures Ltd – 360,000 shares
- Pinkey’s Ltd – 190,500 shares
- Direct holding – 8,687,859 shares
The amendment notes that the percentage ownership has changed because of both the incremental ADS purchases and dilution stemming from a recent increase in the Issuer’s share capital. No new contracts, voting agreements or other material relationships were reported, and a standard joint-filing agreement is included as an exhibit.
Silence Therapeutics plc (SLN) – Form 4 insider transaction. 10% owner Richard Ian Griffiths reported a series of open-market purchases of the company’s American Depositary Shares (ADSs) between 22 and 24 June 2025.
- Griffiths bought 20,977 ADS at $5.84 on 22 Jun, 35,005 ADS at $5.88 on 23 Jun and 26,624 ADS at $6.12 on 24 Jun, totalling 82,606 ADS.
- At the stated prices, the aggregate consideration is approximately US $0.49 million.
- Each ADS represents three ordinary shares; the purchases therefore add about 247,818 ordinary shares to the insider’s economic exposure.
- Following the transactions, Griffiths’ direct holding increased to 11,514,434 ADS, equivalent to roughly 34.5 million ordinary shares, consolidating his status as a 10%+ shareholder.
- All transactions are coded “P” (open-market buy) and were made directly, with no derivative features other than the standard ADS-to-ordinary-share convertibility.
Insider buying by a large, long-term holder is typically interpreted as a positive sentiment signal, suggesting management or significant shareholders view current valuation as attractive. However, the dollar amount, while meaningful, is modest relative to the insider’s existing position, limiting immediate balance-sheet impact.
Silence Therapeutics plc (SLN) – Form 4 insider purchase
On 17 and 18 June 2025, 10% shareholder Richard Ian Griffiths disclosed open-market purchases totaling 70,448 American Depositary Shares (ADS), coded “P”. The transactions were executed at $5.29 and $5.69 per ADS, representing an estimated cash outlay of roughly $0.39 million.
Because each ADS is immediately convertible into three ordinary shares at no additional cost, the buys expand Griffiths’ economic exposure by about 211,344 ordinary shares. His directly held ADS position rose from 11,392,779 to 11,431,828.
The filing did not reference a Rule 10b5-1 trading plan, suggesting discretionary purchases. No insider sales or derivative exercises were reported.
For investors, clustered insider buying by a large, long-tenured holder often serves as a constructive sentiment indicator, especially when executed near multi-year lows (price context not specified in the filing). While modest relative to Griffiths’ total stake, the fresh capital deployment may signal confidence in Silence Therapeutics’ valuation and forthcoming catalysts.